CRISPR/Cpf1 systems and methods
AssigneeIntegrated Dna Technologies, Inc.
InventorsMark Aaron Behlke, Michael Allen Collingwood, Rolf Turk, Christopher Anthony Vakulskas
Life of this patent
Estimating the term…
Abstract
This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
Claims8
An isolated AsCpf1 crRNA, wherein the isolated AsCpf1 crRNA is active in a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein endonuclease system,
- wherein the isolated AsCpf1 crRNA is a length-truncated AsCpf1 crRNA comprising a 5′-universal loop domain of 19 to 20 nucleotides in length and a 3′-target specific protospacer domain of 19 to 21 nucleotides in length and having at least one chemical modification at a position, counting from the 5′-end, selected from the group consisting of:
- RNA residues at position 1, 5, 6, 7, 8, 9, 10, 12, 13, 14, 16, 17, 18, 19, 21, 22, 23, 28, 29, 30, 32, 34, 35, 39, 40, 41, and combinations thereof.
Dependencies are inferred from the claim text.